Diabetic kidney disease has a troubling profile: it is the leading cause of kidney failure in the Western world, affecting millions of people (an estimated 12 million Americans), and there is no cure that stops it. New drugs (SGLT2 inhibitors, GLP-1 agonists) delay the decline but do not halt it. Now, a team of researchers from the Mayo Clinic is examining a different approach: treating the zombie cells that cause inflammation in the kidneys. A new study published in eBioMedicine (from the Lancet group) in February 2026 showed in mice that a combination of dasatinib + quercetin (D+Q) reduces zombie cells, decreases inflammation and kidney damage, and restores protective factors. It is important to clarify upfront: this is a preclinical study, in mice and cultured cells, and not an available treatment for humans. Clinical renal benefit in humans has not yet been demonstrated.
Why do diabetic kidneys develop?
In uncontrolled diabetes, high glucose levels cause chronic damage to the small blood vessels in the kidneys. Over time:
- Reduced filtration: Kidneys do not clean blood effectively
- Protein leaks into urine (proteinuria): An early sign
- Accumulation of toxins: Waste remains in the blood
- Ultimately: kidney failure: Need for dialysis or transplant
Existing treatments help but do not solve the problem. In a significant portion of patients, the disease progresses to kidney failure regardless.
The connection to cellular senescence
For years, information has accumulated on the connection between diabetes and zombie cells. In kidneys and models of diabetic kidney disease, accumulation of senescent cells has been found:
- In tubular epithelial cells
- In filtration units (nephrons)
- In the blood vessels of the kidney
These zombie cells secrete SASP (Senescence-Associated Secretory Phenotype): pro-inflammatory cytokines, abnormal growth factors, and proteases that disrupt the environment. This creates a destructive cycle: inflammation ⟵ more damage ⟵ more zombie cells ⟵ more inflammation.
What are dasatinib + quercetin?
Dasatinib (Sprycel) is an approved drug for types of leukemia (CML, ALL). It inhibits kinases and activates programmed cell death in cells that rely on certain anti-apoptotic pathways.
Quercetin is a natural flavonoid found in onions, apples, berries, and green tea. At high concentrations, it also contributes to activating cell death in senescent cells.
The combination D+Q was described in 2015 (Zhu et al., Aging Cell) as the first senolytic. Together, the two act on different pathways and are more effective than either alone in eliminating zombie cells.
The new study (2026): In diabetic mice
In the study published in eBioMedicine in February 2026, the researchers induced diabetes in mice (using streptozotocin, a common model for diabetic kidney disease) and then administered D+Q in a short 5-day oral course (dasatinib 5 mg/kg + quercetin 50 mg/kg) versus control. Findings in treated mice:
- Senescence markers (like p16) in the kidney decreased
- Inflammation and kidney tissue damage decreased
- Fibrosis (scarring) in the kidney decreased
- Gerontoprotective factors (like Klotho) were restored
In other words: in mice, the kidneys aged less and functioned better. All these benefits were observed in animals, not in humans.
In cultured human cells
In parallel, the team tested human kidney cells in culture. Adding D+Q eliminated senescent cells while preserving healthy cells, demonstrating the selectivity of the treatment in a controlled system. This is also a laboratory experiment (in vitro), not a treatment in humans.
The background: The early human pilot (2019)
It is important to distinguish between the new study and an earlier, separate study. Back in 2019, the team published a small pilot trial in humans in eBioMedicine (Hickson et al.):
- 9 patients with diabetes and kidney disease
- Received a short course of D+Q ("hit-and-run")
- Biopsies of fat and skin tissue were performed before and after
Results of that pilot:
- Zombie cells (p16, p21) in fat and skin tissue decreased
- Some SASP factors in the bloodstream also decreased
- Only mild side effects
This was the first pilot showing that senolytics indeed reduce zombie cells in humans. But note: it was not a trial measuring benefit in kidney function, and biopsies were taken from fat and skin (not the kidney). The new study from 2026 is the work in mice, and it did not include human biopsies.
Why specifically examine D+Q?
The researchers note several advantages of the senolytic approach:
1. Mechanistic rationale
Zombie cells are involved in inflammation and damage in diabetic kidneys. Eliminating them targets one of the roots of the process, not just the symptoms.
2. Known drugs
Both components are known: dasatinib is approved for cancer, and quercetin is sold as a supplement. This means repurposing existing substances, rather than developing an entirely new molecule.
3. Synergistic combination
The two together cover different types of zombie cells, and are therefore more effective in combination than either alone.
4. "Hit-and-run" administration
Unlike drugs that need to be taken daily, senolytics are being studied in intermittent administration (short courses from time to time), due to their short half-life. This approach may reduce cumulative exposure, but has not yet been proven effective and safe for kidney disease in humans.
Who might this be relevant for in the future?
If future clinical trials succeed, groups that might benefit include:
- Type 2 diabetes patients with early microalbuminuria: Early intervention
- Diabetic patients with declining eGFR: Attempt to slow progression
- People with non-diabetic CKD (chronic kidney disease): A theoretical direction to test
All of these are future scenarios contingent on clinical proof, not treatment recommendations.
Potential systemic implications
If a senolytic approach ever proves itself in the clinic for diabetic kidney disease:
- Potential savings for healthcare systems: Dialysis costs about $80,000 to $90,000 per year per patient
- Potential improvement in quality of life: Patients with kidney failure suffer greatly
- Boosting the field of senolytics: Success in one indication may encourage research in others
All of these depend on the benefit observed in mice being translated to humans, which has not yet happened.
When in the clinic?
This approach is still in the research phase. Additional clinical trials are needed to test efficacy and safety in humans for the renal indication. Until that happens, there is no available treatment here.
Why not take D+Q on your own?
Dasatinib is a prescription drug with significant side effects (including risk of heart and lung problems). It must not be taken without a doctor. Quercetin as a supplement is relatively safe at low doses, but the high "senolytic" doses being studied are not recommended for self-use, and the senolytic effect in healthy humans is unproven.
What can you do now?
If you have diabetes and want to protect your kidneys, the strongest evidence currently is:
- Good blood sugar control: Personalized HbA1c target (usually around 7%)
- Treatment with an SGLT2 inhibitor: empagliflozin, dapagliflozin, proven to protect the kidneys
- GLP-1 agonist: such as semaglutide, which also has renal benefit in data
- Blood pressure control: Usually a target below 130/80
- Mediterranean diet: Reduces systemic inflammation
- Regular physical activity: Healthy for kidneys and metabolism
All of these should be done under the guidance of your treating physician.
The bottom line
Diabetic kidney disease was considered a decree. The understanding that zombie cells contribute to inflammation and damage opens a new research direction, and dasatinib + quercetin is the leading senolytic being examined in it. The new study from 2026 is encouraging, but it is preclinical, in mice and cultured cells, and has not proven renal benefit in humans. If you have diabetes and your kidneys are starting to show signs of trouble, it is worth asking your doctor about clinical trials, but for now, the proven treatments (blood sugar and blood pressure control, SGLT2 and GLP-1) are the best way to slow progression.
💬 Comments (0)
Be the first to comment on the article.